NorthView Acquisition Corp.
It is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting what are traditionally known as “small cap” companies domiciled in North America, Europe and/or the Asia Pacific (“APAC”) regions that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space which aligns with our management team’s experience in operating health care companies and in drug and device technology development as well as diagnostic and other services. We will search for target companies with enterprise values ranging from $500 million to $2 billion.
(Note: NorthView Acquisition Corp. upsized its SPAC IPO at pricing on Dec. 20, 2021, to 16.5 million units, up from 15 million, at $10 each to raise $165 million. NASDAQ said the IPO would be released on Nasdaq today (Monday, Dec. 20, 2021) for quotation at 2:20 p.m. EST and the stock would be eligible for trading at about 2:30 p.m. EST.)
|Address||207 West 25th St, 9th Floor New York, NY 10001|
|Phone Number||(212) 494-9022|
|View Prospectus:||NorthView Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$165.0 mil|
|Manager / Joint Managers||I-Bankers Securities, Inc. / Dawson James Securities|
|Expected To Trade:||12/20/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|